Lei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lei Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hao Meng
AMB—Institute of Applied Microbiology, ABBt—Aachen Biology and Biotechnology, RWTH Aachen University, Worringerweg 1, D-52074 Aachen, Germany
1 shared publication - Jin Wang
Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA
1 shared publication - Jinbao Li
Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
1 shared publication Kaiping Zhou
China Rehabilitation Research Center, Beijing, China
1 shared publication- Lei Du
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
1 shared publication Lili Tan
Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- 20 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 376
Single-Cell Dissection of the SPP1-CD44 Axis Reveals Microglia-Astrocyte Crosstalk Driving Neuroinflammation in Temporal Lobe Epilepsy
Temporal lobe epilepsy (TLE), one of the most prevalent focal epilepsies, is characterized by aberrant neuron and glial activation, yet the mechanisms driving microglia-astrocyte crosstalk remain elusive. To address this, we performed integrative single-nucleus RNA sequencing (snRNA-seq) analysis on surgically resected human brain tissue samples from a discovery cohort (4 TLE patients vs 4 controls) and a validation cohort (7 focal epilepsy cases vs the same controls). Using Seurat-based clustering, we identified 9 major cell types and further subclustered microglia and astrocytes. Cell–cell communication, gene regulatory networks, and pseudotime analysis were employed to explore the molecular mechanisms of microglia-astrocyte interactions. Results revealed significant expansion of both activated microglial and activated astrocytic subpopulations in TLE patients versus controls. The SPP1-CD44 axis emerged as the dominant pathway mediating their crosstalk, with reactive microglia as primary SPP1 senders and reactive astrocytes as CD44 receivers. The upstream regulators of SPP1-CD44 axis were subsequently explored, and 9 transcription factors (TFs) were identified as key regulators in reactive microglia. Pseudotime analysis further revealed a CD44-associated phenotypic shift from homeostatic to reactive astrocytes, characterized by progressive loss of synaptic regulatory functions and concurrent acquisition of neurotoxic properties during disease progression. Collectively, our multi-cohort snRNA-seq study reveals the SPP1-CD44 axis as a key mediator of neuroinflammatory pathology in TLE, linking microglial activation to astrocytic dysfunction. These findings broaden therapeutic strategies beyond neuronal targets, underscoring glial modulation as a promising adjunctive approach for epilepsy treatment.
- 20 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 376
Single-Cell Dissection of the SPP1-CD44 Axis Reveals Microglia-Astrocyte Crosstalk Driving Neuroinflammation in Temporal Lobe Epilepsy
Temporal lobe epilepsy (TLE), one of the most prevalent focal epilepsies, is characterized by aberrant neuron and glial activation, yet the mechanisms driving microglia-astrocyte crosstalk remain elusive. To address this, we performed integrative single-nucleus RNA sequencing (snRNA-seq) analysis on surgically resected human brain tissue samples from a discovery cohort (4 TLE patients vs 4 controls) and a validation cohort (7 focal epilepsy cases vs the same controls). Using Seurat-based clustering, we identified 9 major cell types and further subclustered microglia and astrocytes. Cell–cell communication, gene regulatory networks, and pseudotime analysis were employed to explore the molecular mechanisms of microglia-astrocyte interactions. Results revealed significant expansion of both activated microglial and activated astrocytic subpopulations in TLE patients versus controls. The SPP1-CD44 axis emerged as the dominant pathway mediating their crosstalk, with reactive microglia as primary SPP1 senders and reactive astrocytes as CD44 receivers. The upstream regulators of SPP1-CD44 axis were subsequently explored, and 9 transcription factors (TFs) were identified as key regulators in reactive microglia. Pseudotime analysis further revealed a CD44-associated phenotypic shift from homeostatic to reactive astrocytes, characterized by progressive loss of synaptic regulatory functions and concurrent acquisition of neurotoxic properties during disease progression. Collectively, our multi-cohort snRNA-seq study reveals the SPP1-CD44 axis as a key mediator of neuroinflammatory pathology in TLE, linking microglial activation to astrocytic dysfunction. These findings broaden therapeutic strategies beyond neuronal targets, underscoring glial modulation as a promising adjunctive approach for epilepsy treatment.
- Open Access
- 3 February 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 836882
Local Anesthetic Ropivacaine Exhibits Therapeutic Effects in Cancers
Despite the significant progress in cancer treatment, new anticancer therapeutics drugs with new structures and/or mechanisms are still in urgent need to tackle many key challenges. Drug repurposing is a feasible strategy in discovering new drugs among the approved drugs by defining new indications. Recently, ropivacaine, a local anesthetic that has been applied in clinical practice for several decades, has been found to possess inhibitory activity and sensitizing effects when combined with conventional chemotherapeutics toward cancer cells. While its full applications and the exact targets remain to be revealed, it has been indicated that its anticancer potency was mediated by multiple mechanisms, such as modulating sodium channel, inducing mitochondria-associated apoptosis, cell cycle arrest, inhibiting autophagy, and/or regulating other key players in cancer cells, which can be termed as multi-targets/functions that require more in-depth studies. In this review, we attempted to summarize the research past decade of using ropivacaine in suppressing cancer growth and sensitizing anticancer drugs both in-vitro and in-vivo, and tried to interpret the underlying action modes. The information gained in these findings may inspire multidisciplinary efforts to develop/discover more novel anticancer agents via drug repurposing.
- 3 February 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 836882
Open AccessLocal Anesthetic Ropivacaine Exhibits Therapeutic Effects in Cancers
Despite the significant progress in cancer treatment, new anticancer therapeutics drugs with new structures and/or mechanisms are still in urgent need to tackle many key challenges. Drug repurposing is a feasible strategy in discovering new drugs among the approved drugs by defining new indications. Recently, ropivacaine, a local anesthetic that has been applied in clinical practice for several decades, has been found to possess inhibitory activity and sensitizing effects when combined with conventional chemotherapeutics toward cancer cells. While its full applications and the exact targets remain to be revealed, it has been indicated that its anticancer potency was mediated by multiple mechanisms, such as modulating sodium channel, inducing mitochondria-associated apoptosis, cell cycle arrest, inhibiting autophagy, and/or regulating other key players in cancer cells, which can be termed as multi-targets/functions that require more in-depth studies. In this review, we attempted to summarize the research past decade of using ropivacaine in suppressing cancer growth and sensitizing anticancer drugs both in-vitro and in-vivo, and tried to interpret the underlying action modes. The information gained in these findings may inspire multidisciplinary efforts to develop/discover more novel anticancer agents via drug repurposing.
- Open Access
- 22 January 2020
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 36 (4) , 389-390
Correction to: novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy
Unfortunately, there are some tiny errors in the data for Fig. 1a-c and Fig. 2a-e in the published online paper. Please see the correct relative data in Ta
- 22 January 2020
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 36 (4) , 389-390
Open AccessCorrection to: novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy
Unfortunately, there are some tiny errors in the data for Fig. 1a-c and Fig. 2a-e in the published online paper. Please see the correct relative data in Ta